Cardiff Oncology (CRDF)
0.94
+0.01 (1.08%)
Upcoming Events
Latest Headlines
FDA grants orphan drug status to Cardiff Oncology's onvansertib for CMML
October 21, 2026 4:11 PM - StreetInsider
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
October 21, 2026 4:05 PM - Globe NewsWire
H.C. Wainwright Upgrades Cardiff Oncology (CRDF) to Buy
September 15, 2026 6:04 AM - StreetInsider
Form 8-K Cardiff Oncology, Inc. For: Sep 14
September 14, 2026 9:28 AM - SEC Filing
Cardiff Oncology and Nerviano settle dispute over onvansertib rights
September 14, 2026 8:31 AM - StreetInsider
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
September 14, 2026 8:30 AM - Globe NewsWire
Form DEFA14A Cardiff Oncology, Inc.
August 26, 2026 4:05 PM - SEC Filing
Form DEF 14A Cardiff Oncology, Inc. For: Aug 26
August 26, 2026 4:01 PM - SEC Filing
Form PRE 14A Cardiff Oncology, Inc. For: Aug 14
August 14, 2026 4:03 PM - SEC Filing
William Blair Downgrades Cardiff Oncology (CRDF) to Market Perform
August 12, 2026 2:28 AM - StreetInsider
Cardiff Oncology, Inc. (CRDF) Misses Q2 EPS by 2c
August 11, 2026 4:38 PM - StreetInsider
Form 8-K Cardiff Oncology, Inc. For: Aug 11
August 11, 2026 4:11 PM - SEC Filing
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
August 11, 2026 4:10 PM - Globe NewsWire
Form 10-Q Cardiff Oncology, Inc. For: Jun 30
August 11, 2026 4:03 PM - SEC Filing
Form SCHEDULE 13G/A Cardiff Oncology, Inc. Filed by: BlackRock, Inc.
July 27, 2026 4:27 PM - SEC Filing
Full Article List
